Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Share-based Compensation (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Share-based Compensation for 15 consecutive years, with $4000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Share-based Compensation fell 92.73% to $4000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $17000.0, a 92.51% decrease, with the full-year FY2024 number at $148000.0, down 49.14% from a year prior.
  • Share-based Compensation was $4000.0 for Q2 2025 at NovaBay Pharmaceuticals, up from $2000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $184000.0 in Q1 2022 to a low of -$208000.0 in Q3 2022.
  • A 5-year average of $42375.0 and a median of $61000.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: plummeted 160.0% in 2021, then skyrocketed 231.62% in 2022.
  • NovaBay Pharmaceuticals' Share-based Compensation stood at -$117000.0 in 2021, then soared by 176.92% to $90000.0 in 2022, then changed by 0.0% to $90000.0 in 2023, then crashed by 87.78% to $11000.0 in 2024, then plummeted by 63.64% to $4000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Share-based Compensation are $4000.0 (Q2 2025), $2000.0 (Q1 2025), and $11000.0 (Q4 2024).